利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.028 秒)

    Method of treating coronary artery disease FGF-2
    2.
    发明授权
    Method of treating coronary artery disease FGF-2 有权
    用FGF-2治疗冠状动脉疾病的方法

    公开(公告)号：US08796211B2

    公开(公告)日：2014-08-05

    申请号：US13088132

    申请日：2011-04-15

    申请人： Martha Jo Whitehouse

    发明人： Martha Jo Whitehouse

    IPC分类号： A61K38/18

    CPC分类号： A61K38/1825 ,  A61K2300/00

    摘要： The present invention provides a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.

    摘要翻译： 本发明提供在药学上可接受的载体中包含0.2μg/ kg至48μg/ kg的SEQ ID NO：2的FGF-2或其血管生成活性片段或突变蛋白的单位剂量组合物。 还提供了一种用于治疗人类患者冠状动脉疾病的方法，包括向所述患者的一个或多个冠状动脉血管或外周静脉施用安全和血管生成有效剂量的重组FGF-2或血管生成活性片段或突变蛋白 其中。 还提供了药物组合物，其在治疗有效的载体中包含治疗有效量的单独或与肝素组合的FGF-2。

    Methods and compositions for the treatment of peripheral artery disease
    3.
    发明授权
    Methods and compositions for the treatment of peripheral artery disease 失效
    用于治疗外周动脉疾病的方法和组合物

    公开(公告)号：US07186407B2

    公开(公告)日：2007-03-06

    申请号：US10845911

    申请日：2004-05-14

    申请人： Martha Jo Whitehouse

    发明人： Martha Jo Whitehouse

    IPC分类号： A61K31/00 ,  A61K38/00 ,  A61K38/16 ,  A61K45/00

    CPC分类号： C07K14/50 ,  A61K38/1825 ,  A61K2300/00

    摘要： Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.

    摘要翻译： 提供了治疗患者外周动脉疾病的组合物和方法。 组合物包含重组成纤维细胞生长因子-2。 以治疗有效量施用成纤维细胞生长因子如FGF-2，以治疗或预防外周动脉疾病，包括跛行和严重肢体缺血。 还提供了包含治疗有效量的FGF-2和药学上可接受的载体的药物组合物。 本发明治疗外周动脉疾病和跛行的方法包括通过动脉内，静脉内或肌肉内输注至少单一剂量的包含FGF的药物组合物，例如FGF-2。 已经认识到，多次给药可能导致增加的益处，包括间歇给药。

    ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2 AND METHOD OF USE
    4.
    发明申请
    ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2 AND METHOD OF USE 有权
    FGF-2的有效单位剂量及其使用方法

    公开(公告)号：US20120289464A1

    公开(公告)日：2012-11-15

    申请号：US13088132

    申请日：2011-04-15

    申请人： Martha Jo Whitehouse

    发明人： Martha Jo Whitehouse

    IPC分类号： A61K38/18 ,  A61P9/10

    CPC分类号： A61K38/1825 ,  A61K2300/00

    摘要： The present invention provides a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.

    摘要翻译： 本发明提供在药学上可接受的载体中包含0.2μg/ kg至48μg/ kg的SEQ ID NO：2的FGF-2或其血管生成活性片段或突变蛋白的单位剂量组合物。 还提供了一种用于治疗人类患者冠状动脉疾病的方法，包括向所述患者的一个或多个冠状动脉血管或外周静脉施用安全和血管生成有效剂量的重组FGF-2或血管生成活性片段或突变蛋白 其中。 还提供了药物组合物，其在治疗有效的载体中包含治疗有效量的单独或与肝素组合的FGF-2。

    Angiogenically effective unit dose of FGF-2 and method of use
    7.
    发明授权
    Angiogenically effective unit dose of FGF-2 and method of use 有权
    FGF-2的血管生成有效单位剂量及其使用方法

    公开(公告)号：US06440934B1

    公开(公告)日：2002-08-27

    申请号：US09385114

    申请日：1999-08-27

    申请人： Martha Jo Whitehouse

    发明人： Martha Jo Whitehouse

    IPC分类号： A61K3800

    CPC分类号： A61K38/1825 ,  A61K2300/00

    摘要： The present invention has multiple aspects. In particular, in one aspect, the present invention is directed to a unit dose composition comprising 0.2 &mgr;g/kg to 48 &mgr;g/kg of an FGF-2 of SEQ ID NO: 2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. In another aspect, the present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. The single unit dose composition of the present invention provides an angiogenic effect in a human CAD patient that lasts six months before re-treatment is required. In another aspect, the present invention is directed to a method of administration which optimizes patient's safety. In this embodiment, fluids, heparin and/or rate of infusion all play a role. In another aspect, the present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier. The magnitude and duration of benefit were unexpected; in addition benefit with the IV route was unexpected.

    摘要翻译： 本发明具有多个方面。 特别地，在一个方面，本发明涉及包含0.2μg/ kg至48μg/ kg的SEQ ID NO：2的FGF-2或其药学上可接受的血管生成活性片段或突变蛋白的单位剂量组合物 可接受的载体 另一方面，本发明涉及一种治疗冠状动脉疾病的人类患者的方法，其包括对需要治疗冠状动脉疾病的人类患者的一个或多个冠状动脉血管或外周静脉施用安全和血管生成 有效剂量的重组FGF-2或其血管生成活性片段或突变蛋白。 本发明的单一单位剂量组合物在需要再治疗前6个月的人CAD患者中提供血管生成作用。 另一方面，本发明涉及优化患者安全性的给药方法。 在该实施方案中，流体，肝素和/或输注速率都起作用。 在另一方面，本发明涉及药物组合物，其在治疗有效的载体中包含治疗有效量的单独或与肝素组合的FGF-2。 效益的幅度和持续时间是意想不到的; 另外有利于IV路线是意想不到的。